false
Catalog
Reviewing Treatment Options for Cardiac Amyloidosi ...
2. Current and Emerging Treatment in ATTR-CM
2. Current and Emerging Treatment in ATTR-CM
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Richard Chang's presentation focuses on the treatment landscape for TTR cardiomyopathy, particularly targeted therapies and heart failure GDMT. He discusses the biological mechanism of TTR amyloid, explaining how the liver produces the TTR protein, which can misfold and form amyloid deposits leading to heart complications. Emerging treatments aim to target and stabilize these processes using TTR silencers and stabilizers like tefamidase and acromidase, both FDA approved. CRISPR technology and monoclonal antibodies are also being explored for disease reversal. Clinical trials have shown reductions in mortality and improvement in life quality with these treatments, although challenges remain, such as determining the most effective therapies and combining them optimally. Regarding heart failure GDMT, Dr. Chang highlights benefits from SGLT2 inhibitors and MRAs but notes uncertainty about beta blockers and ACES/inhibitors. Overall, ongoing research aims to enhance early diagnosis and effective treatment.
Keywords
TTR cardiomyopathy
targeted therapies
TTR amyloid
CRISPR technology
clinical trials
heart failure GDMT
×
Please select your language
1
English